When you buy through connexion on our site , we may earn an affiliate commission . Here ’s how it works .
Moderna ’s COVID-19 vaccine is dependable and effective for fry eld 6 to 12 days , the party announced on Monday ( Oct. 25 ) .
The findings are part of a clinical run on the effectualness and refuge of the vaccine in around 5,700 children between the age of 6 months and 12 year ; More than 4,700 children between the long time of 6 and 12 years participated in the study and were given two doses of the vaccine 28 day aside , but at half the dose ( 50 µg ) given to adults ( 100 µg ) .
The researchers found that the vaccine at this dose was " well tolerated , " and side effects were similar to what was seen in adolescents and grownup , consort to a statement . The majority of adverse events were mild or moderate ; and the most common side effect were weariness , headache , fever and injection site pain in the ass , the company say .
Related:14 coronavirus myths busted by science
They also found that the vaccine prompted a " strong immune response " one calendar month after the second Cupid’s disease ; child in this age radical had 1.5 times higher antibody levels than those observed in untried adults , the company said .
Moderna antecedently submitted data to the Food and Drug Administration ( FDA ) to get authorization for use of its vaccinum in people ages 12 to 17 , but the agency has n’t yet responded to the postulation . The troupe now plans to also submit this new data to the FDA and other regulative agency around the world .
— 11 ( sometimes ) deadly diseases that hop across species
— Coronavirus variants : Here ’s how the SARS - CoV-2 mutant stack up
— The deadliest viruses in history
Meanwhile , the researchers will continue to supervise the participant for 12 months after their 2nd dose to evaluate recollective - condition protective covering and safety .
Currently , Moderna is approved for those who are 18 years or old , while Pfizer is approve for those 12 years and older . Pfizer has already posit a request to the FDA to authorize its vaccinum for child ages 5 to 11,Live Science antecedently account .
The FDA ’s consultive committeewill meet on Tuesday ( Oct. 26)to hash out Pfizer ’s petition .
Originally published on Live Science .
